Liver Cancer Diagnostics Market Strategies and Future Growth Factors with Competitive Analysis Report till 2022: North America to Remain Dominant in the Global Liver Cancer Diagnostics Market

Medical organizations as well as leaders in the global pharmaceuticals industry are stepping up their efforts towards development of profound diagnosis for liver cancer. Rising number of deaths caused by liver cancer is taking a toll on governments as people are demanding precision diagnosis and a cure-all for this terminal disease. In a bid to adapt to the urban rat race, millions of consumers have adopted lifestyles that are stemming the occurrence of liver cancer. FactMR has included the latest Forecast report titled “Liver Cancer Diagnostics Market Strategies and Future Growth Factors with Competitive Analysis Report till 2022: North America to Remain Dominant in the Global Liver Cancer Diagnostics Market”, to its vast database.

The global market for liver cancer diagnostics is anticipated to witness significant impact from diagnosis-associated patient compliance trials. Positive attitudes of patients towards certain diagnosis alternatives is decisive in changing future undertakings. Prominent diagnostic tools are likely to be replaced with their upgraded variants. The report has highlighted the influence of government undertakings in offering a better compliance for diagnosis of liver cancer patients.

Get Free Sample Report Here - https://www.factmr.com/connectus/sample?flag=S&rep_id=73

Liver cancer is the form of cancer wherein tissues of liver are affected by hepatitis B or hepatitis C virus. Cancer formed in the tissues of liver is termed as primary liver cancer, while the cancer which spreads to the liver from other parts of the body is known as secondary liver cancer.

FactMR, in its recent study, projects the global liver cancer diagnostics market to register a steady expansion at 5.5% CAGR during the forecast period 2017 to 2022. In 2017, the global market for liver cancer diagnostics is expected to reach nearly US$ 700 Mn in revenues.

Liver cancer, the fifth most common cancer, accounted for 9.1% deaths among all cancer patients worldwide in 2012. Poor survival rate and extremely aggressive nature attributed to liver cancer has made this disease to become an imperative health issue around the world. Various risk factors have been associated with liver cancer, which include hepatitis B virus (HBV), exposure to dietary aflatoxin, alcohol-induced cirrhosis, diabetes, obesity, and infection associated with hepatitis C virus (HCV). As these risk factors are modifiable, a strong prospect has been offered for reducing its prevalence and mortality with the help of preventive strategies including hepatitis immunization and lifestyle modification.

Liver cancer, or, hepatocellular carcinoma (HCC) has been observed to cause a large number of deaths annually. In a bid to prevent liver cancer from reaching the final stage, scientists around the world have developed a slew of improved diagnostic solutions. Newer techniques are being developed for the diagnosis of hepatocellular carcinoma, rendering both partial hepatectomy, and liver transplant safer and more effective. Global leading medical instrument manufacturers are focusing on the development of new novel instruments in order to diagnose liver cancer completely. These factors are estimated to drive growth of the global liver cancer diagnostics market during the forecast period.

Browse Complete Report In-Depth Here - https://www.factmr.com/report/73/liver-cancer-diagnostics-market

Based on test type, biopsy test segment is expected to register the highest CAGR in the market through 2022, followed by LFTs. AFP test is estimated to remain preferred for liver cancer diagnostics in the global market. Revenue from AFP test is expected to account for over half share of the market in 2017, and is estimated to gain 52 BPS in its market share between 2017 and 2022.

Hospital-associated Labs to Remain Sought-after for Liver Cancer Diagnostics

Hospital-associated labs will continue to be sought-after for liver cancer diagnostics across the globe. Liver cancer diagnostics in hospital-associated labs will account for the largest revenues by 2022-end. Independent diagnostic laboratories will remain the second most lucrative end-users in the global liver cancer diagnostics market. In addition, liver cancer diagnostics in cancer research institutes are expected to register the fastest expansion over the forecast period.

Competition Tracking

The report has also profiled leading players in the global liver cancer diagnostics market, which include Illumina, Inc., Foundation Medicine, Inc., Danaher Corporation, Sysmex Corporation, and Biocept, Inc.

Table of Contents

Global Liver Cancer Diagnostics Market - Executive Summary
Global Liver Cancer Diagnostics Market Overview
2.1. Introduction

       2.1.1. Global Liver Cancer Diagnostics Market Taxonomy

       2.1.2. Global Liver Cancer Diagnostics Market Definition

2.2. Global Liver Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022

       2.2.1. Global Liver Cancer Diagnostics Market Y-o-Y Growth

2.3. Global Liver Cancer Diagnostics Market Dynamics

       2.3.1. Drivers

       2.3.2. Restraints

       2.3.3. Trends

2.4. Supply Chain

2.5. Epidemiology

2.6. List of Distributors

2.7. Average Pricing Analysis

2.8. Regulations………………………….Continued

Buy This Report from Here - https://www.factmr.com/checkout/73/S

About FactMR

FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Sports market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us -

FactMR
Suite 9884
27 Upper Pembroke Street, Dublin 2, Ireland
Telephone @ +353-1-6111-593
Email: sales@factmr.com
Website: https://www.factmr.com/

This release was published on openPR.